Securities code: 688166 securities abbreviation: Brightgene Bio-Medical Technology Co.Ltd(688166) Announcement No.: 2022-003 Borui biomedical (Suzhou) Co., Ltd
Announcement of issuance results of convertible corporate bonds to unspecified objects sponsor (lead underwriter):
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal liabilities for the authenticity, accuracy and integrity of its contents according to law.
Borui biomedicine (Suzhou) Co., Ltd. (hereinafter referred to as ” Brightgene Bio-Medical Technology Co.Ltd(688166) ” or “issuer”) has obtained the consent note of CSRC zjxk [2021] No. 3551 for issuing convertible corporate bonds (hereinafter referred to as “convertible bonds”) to unspecified objects. Minsheng Securities Co., Ltd. (hereinafter referred to as “Minsheng securities”, “sponsor (lead underwriter)” and “lead underwriter”) are the sponsor (lead underwriter) of this offering. The convertible corporate bonds issued this time are referred to as “Borui convertible bonds” for short, and the bond code is “118004”. The scale of the convertible bonds issued this time is 465 million yuan, which is preferentially placed to the original shareholders registered by China Securities Depository and Clearing Co., Ltd. Shanghai Branch (hereinafter referred to as “China Securities Depository and clearing Shanghai Branch”) after the closing of the market on the equity registration date (December 31, 2021, t-1), The balance after the preferential placement of the original shareholders (including the part abandoned by the original shareholders) is sold online to public investors through the trading system of Shanghai Stock Exchange (hereinafter referred to as “Shanghai Stock Exchange”). If the subscription is less than 465 million yuan, the balance of the recommendation institution (lead underwriter) shall underwrite.
1、 Priority placement results of the original shareholders of convertible bonds
The payment for the preferential placement of the original shareholders of this offering has been completed on January 4, 2022 (t day). The placement results are as follows:
Category placing quantity (hand) placing amount (yuan)
Original shareholder 259185 259185000
2、 Online subscription results of convertible bonds
Online of the balance after the preferential placement of the original shareholders (including the preferential placement abandoned by the original shareholders) in this issuance
The subscription and payment work has been completed on January 6, 2022 (T + 2). According to the data provided by Shanghai Stock Exchange and China Clearing Shanghai Branch, the sponsor (lead underwriter) made statistics on the final subscription of this online issuance of convertible bonds, and the results are as follows:
Category payment subscription quantity payment subscription amount abandonment subscription quantity abandonment subscription amount (hand) (yuan) (hand) (yuan)
Online social public investors 201149 201149000 4666 4666000
3、 Underwriting by the sponsor (lead underwriter)
The number of subscriptions abandoned by online investors this time is underwritten by the sponsor (lead underwriter). The sponsor (lead underwriter) underwrites 4666 hands, the underwriting amount is 4666000 yuan, and the underwriting proportion is 1.00%. On January 10, 2022 (T + 4), the sponsor (lead underwriter) transferred the underwriting funds together with the funds subscribed by investors after deducting the underwriting fees to the issuer. The issuer submitted a bond registration application to China Clearing Shanghai branch and registered the underwritten convertible bonds to the securities account designated by the sponsor (lead underwriter).
4、 Contact information of sponsor (lead underwriter)
(I) issuer
Name: Borui biomedical (Suzhou) Co., Ltd
Legal representative: Yuan Jiandong
Address: building C25, nanotechnology Park, No. 218, Xinghu street, Suzhou Industrial Park
Tel.: 0512-62620988
Contact: Ding Nan
(II) recommendation institution (lead underwriter)
Name: Minsheng Securities Co., Ltd
Legal representative: Feng Henian
Address: No. 8, Puming Road, China (Shanghai) pilot Free Trade Zone
Tel.: 010-85127979, 010-85120190 contact: capital market department
Issuer: Borui biomedicine (Suzhou) Co., Ltd. sponsor (lead underwriter): Minsheng Securities Co., Ltd. January 10, 2022
